Gilead, Ar­cus’ PhII gas­troe­sophageal can­cer da­ta ar­gue for TIG­IT an­ti­body drug class po­ten­tial

Gilead and part­ner Ar­cus Bio­sciences’ an­ti-TIG­IT-based reg­i­men has shown ear­ly signs of ef­fi­ca­cy in a small group of gas­troe­sophageal can­cer pa­tients in a mid-stage tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER